Earnings
Home›Earnings›Results›Tilray reports fiscal Q1 2027 growth as European medic…
Tilray reports fiscal Q1 2027 growth as European medical cannabis rises
Tilray said beverage revenue jumped 82% in fiscal Q1 2027, while European medical cannabis growth helped offset weaker Canadian sales.
Tilray Brands reported first-quarter fiscal 2027 results showing beverage revenue up 82%, according to MarketBeat Ratings.
The company also pointed to growth in European medical cannabis, which it said helped offset weaker Canadian sales, reducing the extent to which it relies on any potential U.S. federal cannabis rescheduling.
MarketBeat Ratings said Tilray currently generates no reported U.S. cannabis revenue, with its domestic operations centered on craft beer, spirits, hospitality, and hemp-based products.
The outlet framed the reported performance as part of Tilray’s broader focus on scaling international medical cannabis and consolidating its beverage alcohol business, based on its fiscal Q1 2027 earnings release.